PepGen Inc. (PEPG): Shareholders' Equity
$147.44M
As of 2025-12-31
$119.53M
As of 2026-06-30
-6.4%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $147.44M | +24.3% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $118.62M | +9.4% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $108.42M | -39.6% | 2025-02-24, Balance as of period end |
| 2022-12-31 | $179.63M | n/m | 2024-03-29, Balance as of period end |
| 2021-12-31 | -$32.08M | n/a | 2023-03-23, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| PepGen Inc. (PEPG) | 2025-12-31 | $147.44M | +24.3% |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$122.76M | n/m |
| Eledon Pharmaceuticals, Inc. (ELDN) | 2025-12-31 | $81.08M | +29.8% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | 2025-12-31 | $147.50M | +3.6% |
| Climb Bio, Inc. (CLYM) | 2025-12-31 | $160.47M | -24.3% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $106.03M | +67.5% |
| Benitec Biopharma Inc. (BNTC) | 2026-06-30 | $177.01M | +81.9% |
| Apimeds Pharmaceuticals US, Inc. (APUS) | 2025-12-31 | $153.35M | n/m |
| Alto Neuroscience, Inc. (ANRO) | 2025-12-31 | $151.14M | -0.2% |
Compare PEPG, GOSS, ELDN, CRBP side by side · Screen every company in Pharmaceutical Preparations ↗